Long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease

被引：167

作者：

Andersson, Helena ^{[1
,2
]}

Sem, Marthe ^{[2
]}

Lund, May Brit ^{[3
]}

Aalokken, Trond Mogens ^{[4
]}

Gunther, Anne ^{[4
]}

Walle-Hansen, Ragnhild ^{[5
]}

Garen, Torhild ^{[2
]}

Molberg, Oyvind ^{[1
,2
]}

机构：

[1] Oslo Univ Hosp, Inst Clin Med, N-0424 Oslo, Norway

[2] Oslo Univ Hosp, Dept Rheumatol, N-0424 Oslo, Norway

[3] Oslo Univ Hosp, Dept Resp Med, N-0424 Oslo, Norway

[4] Oslo Univ Hosp, Dept Radiol, N-0424 Oslo, Norway

[5] Oslo Univ Hosp, Dept Orthopaed Surg, Oslo, Norway

来源：

RHEUMATOLOGY | 2015年 / 54卷 / 08期

关键词：

rituximab; anti-synthetase syndrome; myositis; anti-aminoacyl tRNA synthetase; anti-Jo1; interstitial lung disease; IDIOPATHIC INFLAMMATORY MYOPATHIES; RESOLUTION COMPUTED-TOMOGRAPHY; JUVENILE DERMATOMYOSITIS; PULMONARY-FIBROSIS; REFRACTORY ADULT; POLYMYOSITIS; THERAPY; AUTOANTIBODIES; PNEUMONIA; SURVIVAL;

D O I：

10.1093/rheumatology/kev004

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Objective. To retrospectively evaluate the efficacy and safety of rituximab (Rtx) treatment in patients with anti-synthetase syndrome (ASS) and severe interstitial lung disease (ILD). Methods. Patients with severe ILD and > 12 months follow-up post-Rtx were identified from the Oslo University Hospital ASS cohort (n = 112). Clinical data, including pulmonary function tests (PFTs), were retrospectively collected from medical reports. Extent of ILD pre-, and post-Rtx was scored on thin-section high-resolution CT (HRCT) images and expressed as a percentage of total lung volume. Muscle strength was evaluated by manual muscle testing of eight muscle groups (MMT8). Results. Altogether, 34/112 ASS patients had received Rtx; 24/34 had severe ILD and > 12 months follow-up post-Rtx (median 52 months). In these 24 patients, the median percentage of predicted forced vital capacity, forced expiratory volume in 1 s (FEV1) and diffusing capacity of the lungs for carbon monoxide (DLCO) increased by 24%, 22% and 17%, respectively, post-Rtx. Seven patients (all with disease duration < 12 months and/or acute onset/exacerbation of ILD) had > 30% improvement in all three PFTs. HRCT analysis showed a median 34% reduction in ILD extent post-Rtx. MMT8 score increased post-Rtx. During follow-up, 7/34 (21%) Rtx-treated ASS patients died; 6/7 deaths were related to infections. The mortality rate in the Rtx-treated group was comparable to that of the remaining ASS cohort (25/78 deceased; 32%). Conclusion. This study, which included 24 Rtx-treated ASS patients with severe ILD, reports improved PFTs after a median 52 months follow-up post-Rtx. The best outcome was observed in patients with a disease duration < 12 months and/or acute onset/exacerbation of ILD. The study indicates that Rtx could be a treatment option for selected ASS patients, but infections should be given attention. Key words: rituximab, anti-synthetase syndrome, myositis, anti-aminoacyl tRNA

引用

页码：1420 / 1428

页数：9

共 50 条

[21] Prediction of progressive pulmonary fibrosis in patients with anti-synthetase syndrome-associated interstitial lung disease [J].

Fu, Hongyan ;

Zheng, Ziyao ;

Zhang, Zhenping ;

Yang, Yanjuan ;

Cui, Jieda ;

Wang, Zhaojun ;

Xue, Jing ;

Chi, Shuhong ;

Cao, Mengshu ;

Chen, Juan .

CLINICAL RHEUMATOLOGY, 2023, 42 (07) :1917-1929

[22] The long-term outcome of interstitial lung disease with antiaminoacyl-tRNA synthetase antibodies [J].

Tanizawa, Kiminobu ;

Handa, Tomohiro ;

Nakashima, Ran ;

Kubo, Takeshi ;

Hosono, Yuji ;

Watanabe, Kizuku ;

Aihara, Kensaku ;

Ikezoe, Kohei ;

Sokai, Akihiko ;

Nakatsuka, Yoshinari ;

Taguchi, Yoshio ;

Hatta, Kazuhiro ;

Noma, Satoshi ;

Kobashi, Yoichiro ;

Yoshizawa, Akihiko ;

Oga, Toru ;

Hirai, Toyohiro ;

Chin, Kazuo ;

Nagai, Sonoko ;

Izumi, Takateru ;

Mimori, Tsuneyo ;

Mishima, Michiaki .

RESPIRATORY MEDICINE, 2017, 127 :57-64

[23] Single-Cell Transcriptomics Reveals Peripheral Immune Responses in Anti-Synthetase Syndrome-Associated Interstitial Lung Disease [J].

Zhu, Lili ;

Cao, Zhong ;

Wang, Shiyao ;

Zhang, Changshui ;

Fang, Lei ;

Ren, Yanhong ;

Xie, Bingbing ;

Geng, Jing ;

Xie, Sheng ;

Zhao, Ling ;

Ma, Li ;

Dai, Huaping ;

Wang, Chen .

FRONTIERS IN IMMUNOLOGY, 2022, 13

[24] Long-term clinical prognosis of anti-aminoacyl-tRNA synthetase antibodies and interstitial lung disease [J].

Yamaguchi, Koichi ;

Sullivan, Daniel I. ;

Khushboo, Singh ;

Saygin, Didem ;

Laverde, Silvia Martinez ;

Moghadam-Kia, Siamak ;

Ascherman, Dana P. ;

Oddis, Chester V. ;

Aggarwal, Rohit .

CLINICAL RHEUMATOLOGY, 2025, 44 (08) :3341-3352

[25] Long-term clinical course of anti-glycyl tRNA synthetase (anti-EJ) antibody-related interstitial lung disease pathologically proven by surgical lung biopsy [J].

Sasano, Hajime ;

Hagiwara, Eri ;

Kitamura, Hideya ;

Enomoto, Yasunori ;

Matsuo, Norikazu ;

Baba, Tomohisa ;

Iso, Shinichiro ;

Okudela, Koji ;

Iwasawa, Tae ;

Sato, Shinji ;

Suzuki, Yasuo ;

Takemura, Tamiko ;

Ogura, Takashi .

BMC PULMONARY MEDICINE, 2016, 16

[26] Anti-synthetase syndrome-associated interstitial lung disease possibly caused by atezolizumab in a patient with lung adenocarcinoma: a case report [J].

Miyamoto, Ippei ;

Shimizu, Tetsuo ;

Kusahana, Ryo ;

Nomoto, Masayuki ;

Fujiwara, Daishi ;

Nishizawa, Tsukasa ;

Hayashi, Kentaro ;

Nakagawa, Yoshiko ;

Gon, Yasuhiro .

BMC PULMONARY MEDICINE, 2023, 23 (01)

[27] Clinical characteristics of interstitial lung diseases positive to different anti-synthetase antibodies [J].

Jiang, Minna ;

Dong, Xin ;

Zheng, Yi .

MEDICINE, 2021, 100 (19) :E25816

[28] Long-term treatment with human immunoglobulin for antisynthetase syndrome-associated interstitial lung disease [J].

Huapaya, J. A. ;

Hallowell, R. ;

Silhan, L. ;

Pinal-Fernandez, I. ;

Casal-Dominguez, M. ;

Johnson, C. ;

Albayda, J. ;

Paik, J. J. ;

Lin, C. T. ;

Hussien, A. ;

Mammen, A. L. ;

Christopher-Stine, L. ;

Danoff, S. K. .

RESPIRATORY MEDICINE, 2019, 154 :6-11

[29] Long-Term Treatment With Azathioprine and Mycophenolate Mofetil for Myositis-Related Interstitial Lung Disease [J].

Huapaya, Julio ;

Silhan, Leann ;

Pinal-Fernandez, Iago ;

Casal-Dominguez, Maria ;

Johnson, Cheilonda ;

Albayda, Jemima ;

Paik, Julie ;

Sanyal, Abanti ;

Mammen, Andrew ;

Christopher-Stine, Lisa ;

Danoff, Sonye .

CHEST, 2019, 156 (05) :896-906

[30] Successful baricitinib treatment of refractory anti-synthetase syndrome associated with interstitial lung disease [J].

Sugino, Keishi ;

Ono, Hirotaka ;

Saito, Mikako ;

Ando, Masahiro ;

Tsuboi, Eiyasu .

RESPIROLOGY CASE REPORTS, 2023, 11 (04)

← 1 2 3 4 5 →